|
Sign In to gain access to subscriptions and/or personal tools.
|
Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes
Ralf Dechend
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
Erdenechimeg Shagdarsuren
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany, Novartis Institue for Biomedical Research, East Hanover, New Jersey, USA
Petra Gratze
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
Anette Fiebeler
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
Bernhard Pilz
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
Silke Meiners
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
Wolfgang Derer
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany
David L Feldman
Novartis Institue for Biomedical Research, East Hanover, New Jersey, USA
Randy Webb
Novartis Institue for Biomedical Research, East Hanover, New Jersey, USA
Dominik N Muller
Universitary Medicine Berlin, Charite Campus Buch, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Germany, dominikmueller{at}mdc-berlin.de, Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
We studied the effects of extremely low-dose human renin inhibition (aliskiren) with low angiotensin II receptor blockade (losartan) in a novel double-transgenic rat model harbouring both human renin and angiotensinogen genes. We found that low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal, non-significant, effects on blood pressure (BP). Our data suggest that renin-angiotensin system (RAS) inhibition ameliorates target-organ damage in an Ang II-driven model of hypertension. Direct renin inhibition is equally efficacious in this regard. Our study does not fully answer the question of BP-lowering versus RAS inhibition. This question is important and was at least partially addressed with our low-dose model.
Key Words: angiotensin II • renin inhibitor • inflammation • albuminuria • cardiac damage
References
- Ganten D., Wagner J., Zeh K. et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992;89:7806-10.[Abstract/Free Full Text]
- Mervaala E., Muller DN, Schmidt F. et al. Blood pressureindependent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.[Abstract/Free Full Text]
- Muller DN, Shagdarsuren E., Park JK et al. Immunosuppressive treatment protects against angiotensin IIinduced renal damage. Am J Pathol 2002;161:1679-93.[Abstract/Free Full Text]
- Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.[Abstract/Free Full Text]
- Shagdarsuren E., Wellner M., Braesen JH et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005;97:716-24.[Abstract/Free Full Text]
- Weir MR, Dzau VJ The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12:205S-213S.[Web of Science][Medline]
[Order article via Infotrieve]
- Mervaala EMA, Muller DN, Schmidt F. et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000;35:587-94.[Abstract/Free Full Text]
- Bidani AK, Griffin KA Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004;44:595-601.[Abstract/Free Full Text]
- Ichihara A., Hayashi M., Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the `handle` region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nguyen G., Delarue F., Burckle C. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 8, No. 2,
81-84 (2007)
DOI: 10.3317/jraas.2007.008
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
V. P. Singh, B. Le, R. Khode, K. M. Baker, and R. Kumar
Intracellular Angiotensin II Production in Diabetic Rats Is Correlated With Cardiomyocyte Apoptosis, Oxidative Stress, and Cardiac Fibrosis
Diabetes,
December 1, 2008;
57(12):
3297 - 3306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Feldt, U. Maschke, R. Dechend, F. C. Luft, and D. N. Muller
The Putative (Pro)renin Receptor Blocker HRP Fails to Prevent (Pro)renin Signaling
J. Am. Soc. Nephrol.,
April 1, 2008;
19(4):
743 - 748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Feldt, W. W. Batenburg, I. Mazak, U. Maschke, M. Wellner, H. Kvakan, R. Dechend, A. Fiebeler, C. Burckle, A. Contrepas, et al.
Prorenin and Renin-Induced Extracellular Signal-Regulated Kinase 1/2 Activation in Monocytes Is Not Blocked by Aliskiren or the Handle-Region Peptide
Hypertension,
March 1, 2008;
51(3):
682 - 688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fischer, R. Dechend, F. Qadri, M. Markovic, S. Feldt, F. Herse, J.-K. Park, A. Gapelyuk, I. Schwarz, U. B. Zacharzowsky, et al.
Dietary n-3 Polyunsaturated Fatty Acids and Direct Renin Inhibition Improve Electrical Remodeling in a Model of High Human Renin Hypertension
Hypertension,
February 1, 2008;
51(2):
540 - 546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
